Clinical Trial Update: Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the effect of octreotide acetate on circulating chromogranin A levels in patients with advanced prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• OCTREOTIDE ACETATE (octreotide acetate)

Snippet

Sponsor: Novartis | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED